Literature DB >> 20541668

Molecular genetics of the aip gene in familial pituitary tumorigenesis.

Asil Tahir1, Harvinder S Chahal, Márta Korbonits.   

Abstract

Pituitary adenomas usually occur as sporadic tumors, but familial cases are now increasingly identified. As opposed to multiple endocrine neoplasia type 1 and Carney complex, in familial isolated pituitary adenoma (FIPA) syndrome no other disease is associated with the familial occurrence of pituitary adenomas. It is an autosomal dominant disease with incomplete variable penetrance. Approximately 20% of patients with FIPA harbour germline mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene located on 11q13. Patients with AIP mutations have an overwhelming predominance of somatotroph and lactotroph adenomas, which often present in childhood or young adulthood. AIP, originally identified as a molecular co-chaperone of several nuclear receptors, is thought to act as a tumor suppressor gene; overexpression of wild-type, but not mutant AIP, reduces cell proliferation while knockdown of AIP stimulates it. AIP is shown to bind various proteins, including the aryl hydrocarbon receptor, Hsp90, phosphodiesterases, survivin, RET and the glucocorticoid receptor, but currently it is not clear which interaction has the leading role in pituitary tumorigenesis. This chapter summarizes the available clinical and molecular data regarding the role of AIP in the pituitary gland. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20541668     DOI: 10.1016/S0079-6123(10)82010-2

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  8 in total

Review 1.  Familial isolated pituitary adenomas: from genetics to therapy.

Authors:  Federica Guaraldi; Roberto Salvatori
Journal:  Clin Transl Sci       Date:  2011-02       Impact factor: 4.689

Review 2.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

Review 3.  The glucocorticoid receptor and its expression in the anterior pituitary and the adrenal cortex: a source of variation in hypothalamic-pituitary-adrenal axis function; implications for pituitary and adrenal tumors.

Authors:  George Briassoulis; Svetozar Damjanovic; Paraskevi Xekouki; Hervé Lefebvre; Constantine A Stratakis
Journal:  Endocr Pract       Date:  2011 Nov-Dec       Impact factor: 3.443

4.  Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor.

Authors:  Federica Guaraldi; Valentina Corazzini; Gary L Gallia; Silvia Grottoli; Karen Stals; Nadezhda Dalantaeva; Lawrence A Frohman; Márta Korbonits; Roberto Salvatori
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

Review 5.  Familial isolated pituitary adenomas: an emerging clinical entity.

Authors:  F Martucci; G Trivellin; M Korbonits
Journal:  J Endocrinol Invest       Date:  2012-12       Impact factor: 4.256

6.  Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families.

Authors:  Susana Igreja; Harvinder S Chahal; Peter King; Graeme B Bolger; Umasuthan Srirangalingam; Leonardo Guasti; J Paul Chapple; Giampaolo Trivellin; Maria Gueorguiev; Katie Guegan; Karen Stals; Bernard Khoo; Ajith V Kumar; Sian Ellard; Ashley B Grossman; Márta Korbonits
Journal:  Hum Mutat       Date:  2010-08       Impact factor: 4.878

7.  Multiple endocrine neoplasia 2a presenting with pheochromocytoma and pituitary macroadenoma.

Authors:  Jonathan E Heinlen; David D Buethe; Daniel J Culkin; Gennady Slobodov
Journal:  ISRN Oncol       Date:  2011-04-18

Review 8.  Genetics of Acromegaly and Gigantism.

Authors:  Anna Bogusławska; Márta Korbonits
Journal:  J Clin Med       Date:  2021-03-29       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.